Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
14.73
-0.41 (-2.68%)
Nov 16, 2026, 4:00 PM EST - Market closed

Attovia Therapeutics Earnings Call Transcripts

Fiscal Year 2026

  • Single-dose ATTO-1310 produced durable itch and skin-lesion improvements through week 12 in chronic pruritus and high-itch AD, supporting quarterly dosing. Phase II ATTUNE studies are expected to dose first patients in H1 2027.

  • The session highlighted rapid progress in developing modular nanobody-based biologics for immune-mediated diseases, with ATTO-1310 showing strong early efficacy and safety in chronic itch. Upcoming phase II trials target large unmet needs, while the pipeline expands into bispecific and trispecific assets, all supported by a robust financial position.